Novo Nordisk’s mAb for MACE risk reduction fails in Phase III trial
Novo Nordisk’s monoclonal antibody (mAb) designed to reduce the risk of major adverse cardiovascular events (MACE) in patients…
Sublingual semaglutide offered to UK practices despite Novo Nordisk concerns
An unlicensed semaglutide-based product that is administered under the tongue is being marketed to private doctors in the…
Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk
The market for anti-obesity drugs seems to be at risk of calcifying into a dominant duopoly. Eli Lilly…
Novo Nordisk Real-World Data Supports Ozempic Against LLY’s Mounjaro
Novo Nordisk NVO announced new real-world findings showing that adults with type II diabetes (T2D) who escalated from Ozempic…
UK approves Novo weight-loss pill to edge open European market
By Bhanvi Satija and Christy Santhosh June 11 (Reuters) – Britain’s medicine regulator approved Novo Nordisk’s weight-loss pill…
Novo Nordisk Real-World Data Supports Ozempic Against LLY’s Mounjaro
Novo Nordisk NVO announced new real-world findings showing that adults with type II diabetes (T2D) who escalated from Ozempic…
Berlin hospital discharges US doctor who contracted Ebola
By Milana Vinn NEW YORK, June 6 (Reuters) – A U.S. citizen treated in Germany after contracting Ebola…
Novo Nordisk’s Oral Wegovy Attracts 80% New Patients Ahead of EU Rollout
Nearly 80% of Wegovy pill users are new to GLP-1 drugs, easing cannibalization fears. EU recommends oral 25…
Novo Nordisk Targets Teenage Diabetes Patients as Pipeline Data Looms
Novo Nordisk targets paediatric diabetes with Rybelsus/Ozempic filings, while CagriSema phase-3 results at ADA could shape its next…
Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke
Novo Nordisk A/S The Novo Nordisk study POSEIDON – including 18,904 patients across 18 countries – showed that…
Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke
Novo Nordisk A/S The Novo Nordisk study POSEIDON – including 18,904 patients across 18 countries – showed that…
Europe’s drugs regulator green-lights first oral weight-loss drug – POLITICO
Unlike the weekly Wegovy shot, the tablet is only recommended for adults and has to be taken daily.…